½ÃÀ庸°í¼­
»óǰÄÚµå
1676236

¼¼°èÀÇ °¨¿° °¨½Ã ¼Ö·ç¼Ç ½ÃÀå Á¶»ç º¸°í¼­ : »ê¾÷ ºÐ¼®, ±Ô¸ð, Á¡À¯À², ¼ºÀå, µ¿Çâ, ¿¹Ãø(2025-2033³â)

Global Infection Surveillance Solutions Market Research Report- Industry Analysis, Size, Share, Growth, Trends and Forecast 2025 to 2033

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Value Market Research | ÆäÀÌÁö Á¤º¸: ¿µ¹® 112 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¼¼°èÀÇ °¨¿° °¨½Ã ¼Ö·ç¼Ç ½ÃÀå ±Ô¸ð´Â 2024³â 5¾ï 8,709¸¸ ´Þ·¯¿¡¼­ 2033³â¿¡´Â 18¾ï 3,445¸¸ ´Þ·¯·Î ¼ºÀåÇϸç, 2026-2033³âÀÇ ¿¹Ãø ±â°£ Áß 0.135%ÀÇ °ß°íÇÑ ¿¬°£ Æò±Õ ¼ºÀå·ü(CAGR)À» º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

°¨¿° °¨½Ã ¼Ö·ç¼Ç ½ÃÀåÀº ÀÇ·á ȯ°æ¿¡¼­ È¿°úÀûÀÎ °¨¿° °ü¸® ¹× ¿¹¹æ Àü·«¿¡ ´ëÇÑ ¿ä±¸°¡ Áõ°¡ÇÔ¿¡ µû¶ó Å©°Ô ¼ºÀåÇÒ °ÍÀ¸·Î Àü¸ÁµË´Ï´Ù. Àü ¼¼°è¿¡¼­ ÀÇ·á °ü·Ã °¨¿°(HAI)ÀÇ ºÎ´ãÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ÀÇ·á ½Ã¼³µéÀº °¨¿° ¹ß»ýÀ» ¸ð´ÏÅ͸µÇÏ°í °ü¸®Çϱâ À§ÇØ °ß°íÇÑ °¨½Ã ½Ã½ºÅÛÀ» µµÀÔÇÏ´Â °ÍÀ» ¿ì¼±¼øÀ§·Î »ï°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¼Ö·ç¼ÇÀ» ÅëÇØ ÀÇ·á ¼­ºñ½º ÇÁ·Î¹ÙÀÌ´õ´Â °¨¿°·ü¿¡ ´ëÇÑ µ¥ÀÌÅ͸¦ ¼öÁý, ºÐ¼® ¹× º¸°íÇÏ¿© Àû½Ã¿¡ °³ÀÔÇϰí ȯÀÚÀÇ ¾ÈÀüÀ» Çâ»ó½Ãų ¼ö ÀÖ½À´Ï´Ù. µ¥ÀÌÅÍ ºÐ¼®, ÀΰøÁö´É, ¸Ó½Å·¯´×ÀÇ ±â¼ú Çõ½ÅÀº °¨¿° ¸ð´ÏÅ͸µ ½Ã½ºÅÛÀÇ ±â´ÉÀ» °­È­ÇÏ¿© ½Ç½Ã°£ ¸ð´ÏÅ͸µ°ú ¿¹Ãø ºÐ¼®À» ÅëÇØ °¨¿°ÀÌ È®»êµÇ±â Àü¿¡ ÀáÀçÀûÀÎ °¨¿° ¹ß»ýÀ» ½Äº°ÇÒ ¼ö ÀÖµµ·Ï µ½°í ÀÖ½À´Ï´Ù.

¶ÇÇÑ ±ÔÁ¦ Áؼö¿Í ǰÁú Çâ»ó¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö¸é¼­ °¨¿° °¨½Ã ¼Ö·ç¼Ç ½ÃÀå¿¡µµ ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ½À´Ï´Ù. ÀÇ·á ±â°üÀº ±ÔÁ¦±â°üÀÇ ¾ö°ÝÇÑ °¡À̵å¶óÀΰú º¸°í ±âÁØÀ» ÁؼöÇØ¾ß ÇÏ´Â °æ¿ì°¡ ¸¹¾ÆÁö°í ÀÖÀ¸¸ç, ÀÌ¿¡ µû¶ó ±ÔÁ¤ Áؼö¸¦ º¸ÀåÇÏ´Â Á¾ÇÕÀûÀÎ °¨½Ã ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ºñ¿ë ±â¹Ý Áø·á ¸ðµ¨ÀÇ ºÎ»óÀ¸·Î ÀÇ·á ¼­ºñ½º ÇÁ·Î¹ÙÀÌ´õ°¡ ȯÀÚ ¿¹Èĸ¦ °³¼±ÇÏ°í °¨¿° °ü·Ã ºñ¿ëÀ» Àý°¨ÇÏ´Â µ¥ ÃÊÁ¡À» ¸ÂÃ߸鼭 °¨¿° °¨½Ã ±â¼úÀÇ Ã¤ÅÃÀÌ ´õ¿í °¡¼ÓÈ­µÇ°í ÀÖ½À´Ï´Ù.

¶ÇÇÑ COVID-19 ÆÒµ¥¹ÍÀº °øÁߺ¸°Ç À§±â°ü¸®¿¡¼­ °¨¿° °¨½ÃÀÇ Á߿伺À» ºÎ°¢½ÃÄ×½À´Ï´Ù. °¨¿°º´ÀÇ È¿°úÀûÀÎ ÃßÀû ¹× º¸°íÀÇ Çʿ伺À¸·Î ÀÎÇØ º´¿ø»Ó¸¸ ¾Æ´Ï¶ó °øÁߺ¸°Ç ±â°ü¿¡¼­µµ °¨½Ã ±â¼ú¿¡ ´ëÇÑ ÅõÀÚ°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¸ð¹ÙÀÏ Çコ ¿ëµµ°ú ¿ø°ÝÀÇ·á Ç÷§ÆûÀÇ ÅëÇÕÀº °¨¿° ¸ð´ÏÅ͸µ ¼Ö·ç¼ÇÀÇ Á¢±Ù¼º°ú È¿À²¼ºÀ» ³ô¿© ÀÇ·á ¼­ºñ½º ÇÁ·Î¹ÙÀÌ´õ°¡ ½Ç½Ã°£À¸·Î °¨¿°À» ¸ð´ÏÅ͸µÇÏ°í »õ·Î¿î À§Çù¿¡ ½Å¼ÓÇÏ°Ô ´ëÀÀÇÒ ¼ö ÀÖµµ·Ï µ½°í ÀÖ½À´Ï´Ù. ¿ä¾àÇϸé, °¨¿° ¸ð´ÏÅ͸µ ¼Ö·ç¼Ç ½ÃÀåÀº ±â¼ú ¹ßÀü, ±ÔÁ¦ Áؼö¿¡ ´ëÇÑ °ü½É, ȯÀÚ ¾ÈÀü°ú °øÁß º¸°Ç Çâ»ó¿¡ ´ëÇÑ ³ë·ÂÀ¸·Î ÀÎÇØ °­·ÂÇÑ ¼ºÀå¼¼¸¦ º¸À̰í ÀÖ½À´Ï´Ù.

´ç»çÀÇ º¸°í¼­´Â °í°´¿¡°Ô ´Ù¾çÇÑ »ê¾÷ ¹× ½ÃÀå¿¡ ´ëÇÑ Á¾ÇÕÀûÀÌ°í ½Ç¿ëÀûÀÎ ÀλçÀÌÆ®¸¦ Á¦°øÇϱâ À§ÇØ ¼¼½ÉÇÏ°Ô ÀÛ¼ºµÇ¾ú½À´Ï´Ù. °¢ º¸°í¼­´Â ½ÃÀå »óȲÀ» ¿ÏÀüÈ÷ ÀÌÇØÇϱâ À§ÇØ ¸î °¡Áö Áß¿äÇÑ ¿ä¼Ò¸¦ Æ÷ÇÔÇϰí ÀÖ½À´Ï´Ù.

½ÃÀå °³¿ä : ½ÃÀå °³¿ä : Á¤ÀÇ, ºÐ·ù, »ê¾÷ ÇöȲ µî ½ÃÀå¿¡ ´ëÇÑ ÀÚ¼¼ÇÑ ¼Ò°³.

½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ: ½ÃÀå ¼ºÀå¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â ÁÖ¿ä ÃËÁø¿äÀÎ, ¾ïÁ¦¿äÀÎ, ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ ¹× °úÁ¦¸¦ »ó¼¼ÇÏ°Ô ºÐ¼®ÇÕ´Ï´Ù. ÀÌ ¼½¼Ç¿¡¼­´Â ±â¼ú ¹ßÀü, ±ÔÁ¦ º¯È­, »õ·Î¿î µ¿Çâ µîÀÇ ¿äÀÎÀ» °ËÅäÇÕ´Ï´Ù.

¼¼ºÐÈ­ ºÐ¼® : Á¦Ç° À¯Çü, ¾ÖÇø®ÄÉÀ̼Ç, ÃÖÁ¾»ç¿ëÀÚ, Áö¿ª µîÀÇ ±âÁØ¿¡ µû¶ó ½ÃÀåÀ» ¸íÈ®ÇÑ ºÎ¹®À¸·Î ºÐ·ùÇÕ´Ï´Ù. ÀÌ ºÐ¼®À» ÅëÇØ °¢ ºÎ¹®ÀÇ ¼º°ú¿Í ÀáÀç·ÂÀ» ÆÄ¾ÇÇÒ ¼ö ÀÖ½À´Ï´Ù.

°æÀï»óȲ: ½ÃÀå Á¡À¯À², Á¦Ç° Æ÷Æ®Æú¸®¿À, Àü·«Àû ±¸»ó, À繫½ÇÀû µî ÁÖ¿ä ½ÃÀå ÁøÀÔ±â¾÷¿¡ ´ëÇÑ Á¾ÇÕÀûÀÎ Æò°¡. ÁÖ¿ä ±â¾÷ÀÌ Ã¤ÅÃÇϰí ÀÖ´Â °æÀï ¿ªÇÐ ¹× ÁÖ¿ä Àü·«¿¡ ´ëÇÑ ÀλçÀÌÆ®ÀÌ Æ÷ÇԵǾî ÀÖ½À´Ï´Ù.

½ÃÀå ¿¹Ãø : °ú°Å µ¥ÀÌÅÍ¿Í ÇöÀç ½ÃÀå »óȲÀ» ¹ÙÅÁÀ¸·Î ÀÏÁ¤ ±â°£ Áß ½ÃÀå ±Ô¸ð¿Í ¼ºÀå Ãß¼¼¸¦ ¿¹ÃøÇÕ´Ï´Ù. ¿©±â¿¡´Â Á¤·®Àû ºÐ¼®°ú ¹Ì·¡ ½ÃÀå ±ËÀûÀ» ³ªÅ¸³»´Â ±×·¡ÇÁ Ç¥½Ã°¡ Æ÷ÇԵ˴ϴÙ.

Áö¿ª ºÐ¼® : Áö¿ªº° ½ÃÀå ¼º°ú¸¦ Æò°¡Çϰí ÁÖ¿ä ½ÃÀå ¹× Áö¿ª µ¿ÇâÀ» ÆÄ¾ÇÇÒ ¼ö ÀÖ½À´Ï´Ù. Áö¿ª ½ÃÀå ¿ªÇÐ ¹× ºñÁî´Ï½º ±âȸ¸¦ ÀÌÇØÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù.

»õ·Î¿î µ¿Çâ°ú ±âȸ: ÇöÀç ½ÃÀå µ¿Çâ°ú »õ·Î¿î ½ÃÀå µ¿Çâ, ±â¼ú Çõ½Å, ÀáÀçÀû ÅõÀÚ ´ë»ó ºÎ¹®À» ½Äº°ÇÕ´Ï´Ù. ¹Ì·¡ ½ÃÀå °³¹ß ¹× ¼ºÀå Àü¸Á¿¡ ´ëÇÑ ÀλçÀÌÆ®¸¦ Á¦°øÇÕ´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå °³¿ä

  • ½ÃÀåÀÇ ÇÏÀ̶óÀÌÆ®
  • ¼¼°è ½ÃÀå ½º³À¼ô

Á¦3Àå °¨¿° °¨½Ã ¼Ö·ç¼Ç »ê¾÷ ºÐ¼®

  • ¼­·Ð : ½ÃÀå ¿ªÇÐ
  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
  • ½ÃÀå ±âȸ
  • »ê¾÷ µ¿Çâ
  • Porter's Five Forces ºÐ¼®
  • ½ÃÀåÀÇ ¸Å·Â ºÐ¼®

Á¦4Àå ¹ë·ùüÀÎ ºÐ¼®

  • ¹ë·ùüÀÎ ºÐ¼®
  • ¿ø·á ºÐ¼®
    • ¿ø·á ¸®½ºÆ®
    • ¿ø·á Á¦Á¶¾÷ü ¸®½ºÆ®
    • ÁÖ¿ä ¿ø·áÀÇ °¡°Ý µ¿Çâ
  • ÀáÀçÀû ¹ÙÀÌ¾î ¸®½ºÆ®
  • ¸¶ÄÉÆÃ Ã¤³Î
    • Á÷Á¢ ¸¶ÄÉÆÃ
    • °£Á¢ ¸¶ÄÉÆÃ
    • ¸¶ÄÉÆÃ Ã¤³Î ¹ßÀü µ¿Çâ

Á¦5Àå ¼¼°èÀÇ °¨¿° °¨½Ã ¼Ö·ç¼Ç ½ÃÀå ºÐ¼® : Á¦Ç°¡¤¼­ºñ½ºº°

  • Á¦Ç°¡¤¼­ºñ½ºº° °³¿ä
  • Á¦Ç°¡¤¼­ºñ½ºº° °ú°Å¡¤¿¹Ãø µ¥ÀÌÅÍ ºÐ¼®
  • ¼ÒÇÁÆ®¿þ¾î
  • ¼­ºñ½º

Á¦6Àå ¼¼°èÀÇ °¨¿° °¨½Ã ¼Ö·ç¼Ç ½ÃÀå ºÐ¼® : °¨¿° À¯Çüº°

  • °¨¿° À¯Çüº° °³¿ä
  • °¨¿° À¯Çüº° °Å¡¤¿¹Ãø µ¥ÀÌÅÍ ºÐ¼®
  • ¼ö¼ú ºÎÀ§ °¨¿°
  • Ç÷·ù°¨¿°
  • ¿ä·Î °¨¿°

Á¦7Àå ¼¼°èÀÇ °¨¿° °¨½Ã ¼Ö·ç¼Ç ½ÃÀå ºÐ¼® : ÃÖÁ¾»ç¿ëÀÚº°

  • ÃÖÁ¾»ç¿ëÀÚº° °³¿ä
  • ÃÖÁ¾»ç¿ëÀÚº° °ú°Å¡¤¿¹Ãø µ¥ÀÌÅÍ ºÐ¼®
  • º´¿ø
  • Ŭ¸®´Ð
  • ¿Ü·¡ ¼ö¼ú ¼¾ÅÍ

Á¦8Àå ¼¼°èÀÇ °¨¿° °¨½Ã ¼Ö·ç¼Ç ½ÃÀå ºÐ¼® : Áö¿ªº°

  • Áö¿ªº° Àü¸Á
  • ¼­·Ð
  • ºÏ¹Ì ÆÇ¸Å ºÐ¼®
    • °³¿ä, ½ÇÀû°ú ¿¹Ãø
    • ºÏ¹Ì : ºÎ¹®º°
    • ºÏ¹Ì : ±¹°¡º°
    • ¹Ì±¹
    • ij³ª´Ù
    • ¸ß½ÃÄÚ
  • À¯·´ ÆÇ¸Å ºÐ¼®
    • °³¿ä, ½ÇÀû°ú ¿¹Ãø
    • À¯·´ : ºÎ¹®º°
    • À¯·´ : ±¹°¡º°
    • ¿µ±¹
    • ÇÁ¶û½º
    • µ¶ÀÏ
    • ÀÌÅ»¸®¾Æ
    • ·¯½Ã¾Æ
    • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç ÆÇ¸Å ºÐ¼®
    • °³¿ä, ½ÇÀû°ú ¿¹Ãø
    • ¾Æ½Ã¾ÆÅÂÆò¾ç : ºÎ¹®º°
    • ¾Æ½Ã¾ÆÅÂÆò¾ç : ±¹°¡º°
    • Áß±¹
    • Àεµ
    • ÀϺ»
    • Çѱ¹
    • È£ÁÖ
    • µ¿³²¾Æ½Ã¾Æ
    • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ¶óƾ¾Æ¸Þ¸®Ä« ÆÇ¸Å ºÐ¼®
    • °³¿ä, ½ÇÀû°ú ¿¹Ãø
    • ¶óƾ¾Æ¸Þ¸®Ä« : ºÎ¹®º°
    • ¶óƾ¾Æ¸Þ¸®Ä« : ±¹°¡º°
    • ºê¶óÁú
    • ¾Æ¸£ÇîÆ¼³ª
    • Æä·ç
    • Ä¥·¹
    • ±âŸ ¶óƾ¾Æ¸Þ¸®Ä«
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« ÆÇ¸Å ºÐ¼®
    • °³¿ä, ½ÇÀû°ú ¿¹Ãø
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« : ºÎ¹®º°
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« : ±¹°¡º° ¸®½ºÆ®
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ¾Æ¶ø¿¡¹Ì¸®Æ®
    • À̽º¶ó¿¤
    • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
    • ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«

Á¦9Àå °¨¿° °¨½Ã ¼Ö·ç¼Ç ±â¾÷ÀÇ °æÀï ±¸µµ

  • °¨¿° °¨½Ã ¼Ö·ç¼Ç ½ÃÀåÀÇ °æÀï
  • Á¦ÈÞ¡¤Çù·Â¡¤°è¾à
  • ÇÕº´¡¤Àμö
  • ½ÅÁ¦Ç° ¹ß¸Å
  • ±âŸ °³¹ß

Á¦10Àå ±â¾÷ °³¿ä

  • »óÀ§ ±â¾÷ÀÇ ½ÃÀå Á¡À¯À² ºÐ¼®
  • ½ÃÀå ÁýÁßµµ
  • Becton
  • Dickinson And Company(BD)
  • Premier Inc.
  • Wolters Kluwer N.V.
  • Cerner Corporation(Oracle)
  • RLDatix
  • VigiLanz Corporation
  • GOJO Industries Inc.
  • Baxter International Inc.
  • BioMeRieux SA
  • IBM Corporation(Merative)
  • Epic Systems Corporation
  • Theradoc(Premier Inc.)
  • BioVigil Healthcare Systems Inc.
  • Ecolab Inc.
  • Asolva Inc
KSA 25.04.10

Global Infection Surveillance Solutions Market size is anticipated to grow from USD 587.09 Million in 2024 to USD 1834.45 Million by 2033, showcasing a robust Compound Annual Growth Rate (CAGR) of 0.135% during the forecast period of 2026 to 2033.

The infection surveillance solutions market is poised for significant growth, driven by the increasing need for effective infection control and prevention strategies in healthcare settings. As the global burden of healthcare-associated infections (HAIs) continues to rise, healthcare facilities are prioritizing the implementation of robust surveillance systems to monitor and manage infection outbreaks. These solutions enable healthcare providers to collect, analyze, and report data on infection rates, facilitating timely interventions and improving patient safety. Innovations in data analytics, artificial intelligence, and machine learning are enhancing the capabilities of infection surveillance systems, allowing for real-time monitoring and predictive analytics that can identify potential outbreaks before they escalate.

Moreover, the growing emphasis on regulatory compliance and quality improvement initiatives is influencing the infection surveillance solutions market. Healthcare organizations are increasingly required to adhere to stringent guidelines and reporting standards set by regulatory bodies, driving the demand for comprehensive surveillance solutions that ensure compliance. Additionally, the rise of value-based care models is prompting healthcare providers to focus on improving patient outcomes and reducing costs associated with infections, further fueling the adoption of infection surveillance technologies.

Furthermore, the COVID-19 pandemic has underscored the importance of infection surveillance in managing public health crises. The need for effective tracking and reporting of infectious diseases has led to increased investments in surveillance technologies, not only in hospitals but also in public health agencies. The integration of mobile health applications and telehealth platforms is also enhancing the accessibility and efficiency of infection surveillance solutions, enabling healthcare providers to monitor infections in real-time and respond swiftly to emerging threats. In summary, the infection surveillance solutions market is set for robust growth, characterized by technological advancements, a focus on regulatory compliance, and a commitment to improving patient safety and public health.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

SEGMENTATION COVERED IN THE REPORT

By Products and Services

  • Software
  • Services

By Infection Type

  • Surgical Site Infections
  • Blood Stream Infections
  • Urinary Tract Infections

By End User

  • Hospitals
  • Clinics
  • Ambulatory Surgical Centers
  • Other
  • COMPANIES PROFILED
  • Baxter
  • BD
  • STERIS
  • Getinge AB
  • Medtronic
  • Koninklijke Philips N.V.
  • Abbott
  • Medexter Healthcare
  • Asolva
  • GOJO Industries Inc
  • Wolters Kluwer N.V.
  • VigiLanz Corporation
  • RLDatix
  • Roper Technologies Inc
  • Health Outcomes Worldwide
  • OpGen Inc
  • Urovant Sciences and Premier
  • The above list can be customized.

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Report Description
    • 1.1.1 Objective
    • 1.1.2 Target Audience
    • 1.1.3 Unique Selling Proposition (USP) & offerings
  • 1.2. Research Scope
  • 1.3. Research Methodology
    • 1.3.1 Market Research Process
    • 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

  • 2.1. Highlights of Market
  • 2.2. Global Market Snapshot

3. INFECTION SURVEILLANCE SOLUTIONS INDUSTRY ANALYSIS

  • 3.1. Introduction - Market Dynamics
  • 3.2. Market Drivers
  • 3.3. Market Restraints
  • 3.4. Opportunities
  • 3.5. Industry Trends
  • 3.6. Porters Five Force Analysis
  • 3.7. Market Attractiveness Analysis
    • 3.7.1 Market Attractiveness Analysis By Products and Services
    • 3.7.2 Market Attractiveness Analysis By Infection Type
    • 3.7.3 Market Attractiveness Analysis By End User
    • 3.7.4 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

  • 4.1. Value Chain Analysis
  • 4.2. Raw Material Analysis
    • 4.2.1 List of Raw Materials
    • 4.2.2 Raw Material Manufactures List
    • 4.2.3 Price Trend of Key Raw Materials
  • 4.3. List of Potential Buyers
  • 4.4. Marketing Channel
    • 4.4.1 Direct Marketing
    • 4.4.2 Indirect Marketing
    • 4.4.3 Marketing Channel Development Trend

5. GLOBAL INFECTION SURVEILLANCE SOLUTIONS MARKET ANALYSIS BY PRODUCTS AND SERVICES

  • 5.1. Overview By Products and Services
  • 5.2. Historical and Forecast Data Analysis By Products and Services
  • 5.3. Software Historic and Forecast Sales By Regions
  • 5.4. Services Historic and Forecast Sales By Regions

6. GLOBAL INFECTION SURVEILLANCE SOLUTIONS MARKET ANALYSIS BY INFECTION TYPE

  • 6.1. Overview By Infection Type
  • 6.2. Historical and Forecast Data Analysis By Infection Type
  • 6.3. Surgical Site Infections Historic and Forecast Sales By Regions
  • 6.4. Blood Stream Infections Historic and Forecast Sales By Regions
  • 6.5. Urinary Tract Infections Historic and Forecast Sales By Regions

7. GLOBAL INFECTION SURVEILLANCE SOLUTIONS MARKET ANALYSIS BY END USER

  • 7.1. Overview By End User
  • 7.2. Historical and Forecast Data Analysis By End User
  • 7.3. Hospitals Historic and Forecast Sales By Regions
  • 7.4. Clinics Historic and Forecast Sales By Regions
  • 7.5. Ambulatory Surgical Centers Historic and Forecast Sales By Regions

8. GLOBAL INFECTION SURVEILLANCE SOLUTIONS MARKET ANALYSIS BY GEOGRAPHY

  • 8.1. Regional Outlook
  • 8.2. Introduction
  • 8.3. North America Sales Analysis
    • 8.3.1 Overview, Historic and Forecast Data Sales Analysis
    • 8.3.2 North America By Segment Sales Analysis
    • 8.3.3 North America By Country Sales Analysis
    • 8.3.4 United States Sales Analysis
    • 8.3.5 Canada Sales Analysis
    • 8.3.6 Mexico Sales Analysis
  • 8.4. Europe Sales Analysis
    • 8.4.1 Overview, Historic and Forecast Data Sales Analysis
    • 8.4.2 Europe By Segment Sales Analysis
    • 8.4.3 Europe By Country Sales Analysis
    • 8.4.4 United Kingdom Sales Analysis
    • 8.4.5 France Sales Analysis
    • 8.4.6 Germany Sales Analysis
    • 8.4.7 Italy Sales Analysis
    • 8.4.8 Russia Sales Analysis
    • 8.4.9 Rest Of Europe Sales Analysis
  • 8.5. Asia Pacific Sales Analysis
    • 8.5.1 Overview, Historic and Forecast Data Sales Analysis
    • 8.5.2 Asia Pacific By Segment Sales Analysis
    • 8.5.3 Asia Pacific By Country Sales Analysis
    • 8.5.4 China Sales Analysis
    • 8.5.5 India Sales Analysis
    • 8.5.6 Japan Sales Analysis
    • 8.5.7 South Korea Sales Analysis
    • 8.5.8 Australia Sales Analysis
    • 8.5.9 South East Asia Sales Analysis
    • 8.5.10 Rest Of Asia Pacific Sales Analysis
  • 8.6. Latin America Sales Analysis
    • 8.6.1 Overview, Historic and Forecast Data Sales Analysis
    • 8.6.2 Latin America By Segment Sales Analysis
    • 8.6.3 Latin America By Country Sales Analysis
    • 8.6.4 Brazil Sales Analysis
    • 8.6.5 Argentina Sales Analysis
    • 8.6.6 Peru Sales Analysis
    • 8.6.7 Chile Sales Analysis
    • 8.6.8 Rest of Latin America Sales Analysis
  • 8.7. Middle East & Africa Sales Analysis
    • 8.7.1 Overview, Historic and Forecast Data Sales Analysis
    • 8.7.2 Middle East & Africa By Segment Sales Analysis
    • 8.7.3 Middle East & Africa By Country Sales Analysis
    • 8.7.4 Saudi Arabia Sales Analysis
    • 8.7.5 UAE Sales Analysis
    • 8.7.6 Israel Sales Analysis
    • 8.7.7 South Africa Sales Analysis
    • 8.7.8 Rest Of Middle East And Africa Sales Analysis

9. COMPETITIVE LANDSCAPE OF THE INFECTION SURVEILLANCE SOLUTIONS COMPANIES

  • 9.1. Infection Surveillance Solutions Market Competition
  • 9.2. Partnership/Collaboration/Agreement
  • 9.3. Merger And Acquisitions
  • 9.4. New Product Launch
  • 9.5. Other Developments

10. COMPANY PROFILES OF INFECTION SURVEILLANCE SOLUTIONS INDUSTRY

  • 10.1. Top Companies Market Share Analysis
  • 10.2. Market Concentration Rate
  • 10.3. Becton
    • 10.3.1 Company Overview
    • 10.3.2 Company Revenue
    • 10.3.3 Products
    • 10.3.4 Recent Developments
  • 10.4. Dickinson And Company (BD)
    • 10.4.1 Company Overview
    • 10.4.2 Company Revenue
    • 10.4.3 Products
    • 10.4.4 Recent Developments
  • 10.5. Premier Inc.
    • 10.5.1 Company Overview
    • 10.5.2 Company Revenue
    • 10.5.3 Products
    • 10.5.4 Recent Developments
  • 10.6. Wolters Kluwer N.V.
    • 10.6.1 Company Overview
    • 10.6.2 Company Revenue
    • 10.6.3 Products
    • 10.6.4 Recent Developments
  • 10.7. Cerner Corporation (Oracle)
    • 10.7.1 Company Overview
    • 10.7.2 Company Revenue
    • 10.7.3 Products
    • 10.7.4 Recent Developments
  • 10.8. RLDatix
    • 10.8.1 Company Overview
    • 10.8.2 Company Revenue
    • 10.8.3 Products
    • 10.8.4 Recent Developments
  • 10.9. VigiLanz Corporation
    • 10.9.1 Company Overview
    • 10.9.2 Company Revenue
    • 10.9.3 Products
    • 10.9.4 Recent Developments
  • 10.10. GOJO Industries Inc.
    • 10.10.1 Company Overview
    • 10.10.2 Company Revenue
    • 10.10.3 Products
    • 10.10.4 Recent Developments
  • 10.11. Baxter International Inc.
    • 10.11.1 Company Overview
    • 10.11.2 Company Revenue
    • 10.11.3 Products
    • 10.11.4 Recent Developments
  • 10.12. BioMéRieux SA
    • 10.12.1 Company Overview
    • 10.12.2 Company Revenue
    • 10.12.3 Products
    • 10.12.4 Recent Developments
  • 10.13. IBM Corporation (Merative)
    • 10.13.1 Company Overview
    • 10.13.2 Company Revenue
    • 10.13.3 Products
    • 10.13.4 Recent Developments
  • 10.14. Epic Systems Corporation
    • 10.14.1 Company Overview
    • 10.14.2 Company Revenue
    • 10.14.3 Products
    • 10.14.4 Recent Developments
  • 10.15. Theradoc (Premier Inc.)
    • 10.15.1 Company Overview
    • 10.15.2 Company Revenue
    • 10.15.3 Products
    • 10.15.4 Recent Developments
  • 10.16. BioVigil Healthcare Systems Inc.
    • 10.16.1 Company Overview
    • 10.16.2 Company Revenue
    • 10.16.3 Products
    • 10.16.4 Recent Developments
  • 10.17. Ecolab Inc.
    • 10.17.1 Company Overview
    • 10.17.2 Company Revenue
    • 10.17.3 Products
    • 10.17.4 Recent Developments
  • 10.18. Asolva Inc
    • 10.18.1 Company Overview
    • 10.18.2 Company Revenue
    • 10.18.3 Products
    • 10.18.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies

ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦